

# UCLA

## UCLA Previously Published Works

### Title

Sodium Bicarbonate Use During Pediatric Cardiopulmonary Resuscitation: A Secondary Analysis of the ICU-RESUScitation Project Trial.

### Permalink

<https://escholarship.org/uc/item/56z5b72p>

### Journal

Pediatric Critical Care Medicine, 23(10)

### ISSN

1529-7535

### Authors

Cashen, Katherine  
Reeder, Ron  
Ahmed, Tageldin  
[et al.](#)

### Publication Date

2022-10-01

### DOI

10.1097/PCC.0000000000003045

Peer reviewed



Published in final edited form as:

*Pediatr Crit Care Med.* 2022 October 01; 23(10): 784–792. doi:10.1097/PCC.0000000000003045.

## Sodium Bicarbonate Use during Pediatric Cardiopulmonary Resuscitation: A Secondary Analysis of the ICU-RESUSCitation Project Trial

Katherine Cashen, DO<sup>1</sup>, Ron W Reeder, PhD<sup>2</sup>, Tageldin Ahmed, MD<sup>3</sup>, Michael J Bell, MD<sup>4</sup>, Robert A Berg, MD<sup>5</sup>, Candice Burns, MD<sup>6</sup>, Joseph A Carcillo, MD<sup>7</sup>, Todd C Carpenter, MD<sup>8</sup>, J Michael Dean, MD<sup>2</sup>, J Wesley Diddle, MD<sup>4</sup>, Myke Federman, MD<sup>9</sup>, Ericka L Fink, MD, MS<sup>7</sup>, Aisha H Frazier, MD, MPH<sup>10,11</sup>, Stuart H Friess, MD<sup>12</sup>, Kathryn Graham, MLAS<sup>5</sup>, Mark Hall, MD<sup>13</sup>, David A Hehir, MD<sup>5</sup>, Christopher M Horvat, MD<sup>7</sup>, Leanna L Huard, MD<sup>9</sup>, Tensing Maa, MD<sup>13</sup>, Arushi Manga, MD<sup>12</sup>, Patrick S McQuillen, MD<sup>14</sup>, Ryan W Morgan, MD, MTR<sup>5</sup>, Peter M Mourani, MD<sup>8</sup>, Vinay M Nadkarni, MD, MS<sup>5</sup>, Maryam Y Naim, MD, MSCE<sup>5</sup>, Daniel Notterman, MD<sup>15</sup>, Chella A Palmer, MPH<sup>2</sup>, Murray M Pollack, MD<sup>4</sup>, Carleen Schneiter, MD<sup>8</sup>, Matthew P Sharron, MD<sup>4</sup>, Neeraj Srivastava, MD<sup>9</sup>, David Wessel, MD<sup>4</sup>, Heather A Wolfe, MD, MSHP<sup>5</sup>, Andrew R Yates, MD<sup>13</sup>, Athena F Zuppa, MD<sup>5</sup>, Robert M Sutton, MD, MSCE<sup>5</sup>, Kathleen L Meert, MD<sup>3</sup>

<sup>1</sup>Department of Pediatrics, Duke Children's Hospital, Duke University, Durham, NC, USA

<sup>2</sup>Department of Pediatrics, University of Utah, Salt Lake City, UT, USA

<sup>3</sup>Department of Pediatrics, Children's Hospital of Michigan, Central Michigan University, Detroit, MI, USA

<sup>4</sup>Department of Pediatrics, Children's National Hospital, George Washington University School of Medicine, Washington, DC, USA

<sup>5</sup>Department of Anesthesiology and Critical Care Medicine, The Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA

<sup>6</sup>Department of Pediatrics and Human Development, Michigan State University, Grand Rapids, MI, USA

<sup>7</sup>Department of Critical Care Medicine, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, USA

<sup>8</sup>Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA

<sup>9</sup>Department of Pediatrics, Mattel Children's Hospital, University of California Los Angeles, Los Angeles, CA, USA

<sup>10</sup>Nemours Cardiac Center, Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE, USA

<sup>11</sup>Department of Pediatrics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA

---

**Corresponding Author:** Kathleen L. Meert, MD, Children's Hospital of Michigan, 3901 Beaubien Blvd, Detroit MI, 48201; Phone (313) 745-5891, kmeert@dmc.org.

<sup>12</sup>Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA

<sup>13</sup>Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA

<sup>14</sup>Department of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA, USA

<sup>15</sup>Department of Molecular Biology, Princeton University, Princeton, NJ, USA, and the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network (CPCCRN) and National Heart Lung and Blood Institute ICU-RESUScitation Project Investigators

## Abstract

**Objective:** To evaluate associations between sodium bicarbonate use and outcomes during pediatric in-hospital cardiac arrest (p-IHCA).

**Design:** Pre-specified secondary analysis of a prospective, multicenter cluster randomized interventional trial.

**Setting:** Eighteen participating intensive care units of the ICU-RESUScitation Project ([NCT02837497](#)).

**Patients:** Children 18 years old and 37 weeks post-conceptual age who received chest compressions of any duration from October 2016-March 2021.

**Interventions:** None.

**Measurements and Main Results:** Child and event characteristics, pre-arrest laboratory values (2 to 6 hours prior to p-IHCA), pre- and intra-arrest hemodynamics, and outcomes were collected. In a propensity score weighted cohort, the relationships between sodium bicarbonate use and outcomes were assessed. The primary outcome was survival to hospital discharge. Secondary outcomes included return of spontaneous circulation (ROSC) and survival to hospital discharge with favorable neurologic outcome.

Of 1100 index CPR events, median age was 0.63 years (IQR 0.19, 3.81); 528 (48.0%) received sodium bicarbonate; 773 (70.3%) achieved ROSC; 642 (58.4%) survived to hospital discharge; and 596 (54.2%) survived to hospital discharge with favorable neurologic outcome. Among the weighted cohort, sodium bicarbonate use was associated with lower survival to hospital discharge rate (aOR 0.7; CI95 0.54-0.92, p=0.01) and lower survival to hospital discharge with favorable neurologic outcome rate (aOR: 0.69; CI95 0.53-0.91, p=0.007). Sodium bicarbonate use was not associated with ROSC (aOR: 0.91 (CI95 0.62, 1.34, p=0.621).

**Conclusions:** In this propensity weighted multicenter cohort study of p-IHCA, sodium bicarbonate use was common, and associated with lower rates of survival to hospital discharge.

## Keywords

cardiopulmonary resuscitation; sodium bicarbonate; neonate; infant; child

## INTRODUCTION

Cardiopulmonary resuscitation (CPR) for pediatric in-hospital cardiac arrest (p-IHCA) affects approximately 15,000 children in the United States every year (1,2). During p-IHCA children may develop metabolic acidosis due to tissue hypoxia, resultant anaerobic metabolism, and impaired renal perfusion (2). Historically, sodium bicarbonate has been used during CPR as a buffer to raise the extracellular pH in attempt to counteract the negative effects of metabolic acidosis. However, due to evidence of lack of benefit and potential harm, the American Heart Association (AHA) Pediatric Advanced Life Support guidelines have recommended against the routine use of sodium bicarbonate in cardiac arrest since 2005 (3–9). Sodium bicarbonate may be administered for select scenarios including preexisting metabolic acidosis, hyperkalemia, or tricyclic antidepressant overdose (5–7). Despite these limited indications, two recent registry reports suggest sodium bicarbonate is still used frequently during p-IHCA and associated with decreased survival (10,11).

Prior studies of sodium bicarbonate use during p-IHCA have been single-center or registry reports. While important, these studies are limited due to their retrospective nature and level of detail reported. No multicenter prospective pediatric study has described hemodynamic data associated with sodium bicarbonate use during CPR. The primary objective of our study was to assess the relationships between sodium bicarbonate use during p-IHCA and outcomes. The primary outcome was survival to hospital discharge; secondary outcomes included return of spontaneous circulation (ROSC), survival to hospital discharge with favorable neurologic outcome, and functional status at hospital discharge. Further, we report child and event characteristics, and pre- and intra-arrest hemodynamics associated with sodium bicarbonate use.

## METHODS

The study is a pre-specified secondary analysis of the ICU-RESUScitation (ICU-RESUS) project ([NCT02837497](https://clinicaltrials.gov/ct2/show/study/NCT02837497)). ICU-RESUS was conducted in 18 pediatric intensive care units (PICU) and pediatric cardiac intensive care units (PCICU) across 10 clinical sites from October 2016-March 2021. Eight participating sites were affiliated with the Collaborative Pediatric Critical Care Research Network (CPCCRN). ICU-RESUS evaluated the effectiveness of a CPR quality improvement bundle on improving survival outcomes from ICU pediatric cardiac arrests (12). The bundle was comprised of physiology focused point-of-care CPR training and post-cardiac arrest event debriefings. The institutional review board (IRB) at the University of Utah served as the single IRB and approved the study (#00093320) with waiver of parental permission.

Children were included in ICU-RESUS if they were 18 years old and 37 weeks post-conceptual age and received chest compressions of any duration in an ICU. Children were excluded if, prior to arrest, they had (1) pre-existing terminal illness and were not expected to survive the hospitalization, (2) documented lack of commitment to aggressive ICU therapies, (3) brain death, and (4) an out-of-hospital CPR event associated with the hospital admission. Additionally, children were excluded from this secondary analysis if extracorporeal membrane oxygenation (ECMO) was in use at the start of CPR. Of 1129

index CPR events enrolled in ICU-RESUS, 29 received ECMO at the start of CPR leaving 1100 events for this secondary analysis (Supplemental Digital Content 1). Of these, sodium bicarbonate was used in 528 (48.0%) events (Table 1).

Data were collected at each site by trained research coordinators. Data included child and CPR event characteristics consistent with the Utstein Resuscitation Registry Template for In-Hospital Cardiac Arrest (13,14). For children with invasive arterial catheters, hemodynamic waveforms were collected, and reviewed and analyzed by investigators at the Children's Hospital of Philadelphia as previously described (15,16).

Child characteristics included demographics and preexisting medical conditions. Pre-event characteristics included illness category (medical cardiac, surgical cardiac, non-cardiac), Pediatric Risk of Mortality (PRISM) score (17), vasoactive inotropic score (VIS) (18), highest serum potassium concentration, and presence of hyperkalemia (potassium  $\geq 6$  mmol/L) 2-6 hours prior to CPR. Event characteristics included location of CPR, CPR duration, time of CPR (weekday/weeknight/weekend), first documented rhythm, immediate cause of cardiac arrest, interventions in place at start of CPR, open sternum at start of CPR, sternotomy procedure during CPR, and pharmacologic interventions during CPR. Post-CPR event data included use of ECMO within 6 and 24 hours of CPR, and highest arterial lactate within 6 hours and between 6-24 hours, and highest pH within 6 hours.

Hemodynamic variables included lowest systolic blood pressure 2-6 hours prior to CPR, average systolic and diastolic blood pressures one minute prior to CPR, and average systolic and diastolic blood pressures over the first minute and 10 minutes of CPR. Additional hemodynamic variables included average diastolic blood pressure  $\geq 25$  mmHg for children  $<1$  year of age, and  $\geq 30$  mmHg for children  $\geq 1$  year of age, and average systolic blood pressure  $\geq 60$  mmHg for children  $<1$  year of age, and  $\geq 80$  mmHg for children  $\geq 1$  year of age over the first one minute and ten minutes of CPR.

The primary outcome was survival to hospital discharge. Secondary outcomes included ROSC, survival to hospital discharge with favorable neurologic outcome, functional status at hospital discharge in survivors, and presence of a new morbidity. Neurologic outcome was based on the Pediatric Cerebral Performance Category (PCPC). Favorable neurologic outcome was defined as PCPC score of 1 (normal), 2 (mild disability) or 3 (moderate disability), or no worse than baseline score (19). Functional outcome was assessed using the Functional Status Scale (FSS); absolute change from baseline to hospital discharge in survivors was reported (20). New morbidity was defined as worsening from baseline FSS by 3 or more points.

### Statistical Analysis

Child and event characteristics were summarized with counts and percentages for categorical variables and medians and quartiles for continuous variables (Table 1 and Supplemental Digital Content 2). Differences in event characteristics between those with versus without sodium bicarbonate use were evaluated with Fisher's exact test, Wilcoxon rank-sum test, and the Cochran-Armitage trend test, as appropriate. Hemodynamic variables were similarly reported by age (Supplemental Digital Content 3). Outcomes were summarized similarly but

without statistical testing (Table 2) because a more careful analysis was warranted to account for potential confounding factors.

To assess the effect of sodium bicarbonate on outcomes, propensity weighted regression was used to reduce potential confounding from a priori factors (21). This robust approach involves three main steps. First, a logistic regression model of sodium bicarbonate use was created to estimate each subject's probability (propensity) for receiving sodium bicarbonate (Supplemental Digital Content 4). Variables included in the model were study site, age, illness category, sepsis, PRISM components, VIS, first documented rhythm, hypotension as immediate cause of arrest, and duration of CPR. A histogram of propensities was created for those with versus without sodium bicarbonate use (Supplemental Digital Content 5). Eleven subjects with a propensity for sodium bicarbonate use  $<0.02$  and seven with propensity  $>0.98$  were excluded from further analysis because there were no comparable subjects in the opposite treatment group.

Second, subjects were weighted using stabilized inverse probability of treatment weights. This weighting increases the balance of a priori characteristics between those with versus without sodium bicarbonate use, creating a weighted cohort in which subjects differ with respect to sodium bicarbonate use but are balanced with respect to potentially confounding characteristics (Supplemental Digital Content 6). This is the mechanism by which confounding from characteristics is reduced. Thus, the level of balance obtained is critical. Differences in means and proportions were compared between those with versus without sodium bicarbonate use. When means between groups differed by less than one-tenth of a standard deviation, i.e. absolute standardized difference  $<0.10$ , the groups were considered well balanced (21).

Third, regression models were built using the weighted cohort to assess the effect of sodium bicarbonate on outcomes (Table 3). Ordinary linear regression was used for continuous outcomes, and logistic regression was used for binary outcomes. These models controlled for four a priori selected variables (first documented rhythm, age, illness category, and CPR duration) to further reduce potential confounding from these variables and reduce the unexplained variability in the models to improve power (22,23). These models also controlled for variables that could not be balanced by the propensity score (Sites D and J and creatinine). All analyses were performed using SAS 9.4 (SAS Institute; Cary, NC) with reported p-value based on a two-sided alternative and considered significant if less than 0.05.

## RESULTS

Of 1100 index CPR events, median age was 0.63 years (IQR 0.19, 3.81); 589 (53.5%) events were in males and the most common preexisting medical condition was respiratory insufficiency (Table 1). CPR event characteristics are shown in Supplemental Digital Content 2. Sodium bicarbonate use was more common in medical cardiac and surgical cardiac patients than non-cardiac patients. Sodium bicarbonate was used more often in children with higher PRISM and VIS scores. Few children ( $n=30$ ) had hyperkalemia, and sodium bicarbonate use was similar between those with and without hyperkalemia. Children with p-IHCA in a PCICU received sodium bicarbonate more often than those in

a PICU. Longer CPR duration, pulseless electrical activity (PEA)/asystole and ventricular fibrillation/tachycardia as the first documented rhythm and hypotension as the immediate cause of arrest were associated with sodium bicarbonate use. Sodium bicarbonate use was associated with having an open sternum at the start of CPR and sternotomy procedure during CPR. Sodium bicarbonate use was associated with additional pharmacologic interventions during CPR including epinephrine, atropine, calcium, vasopressin, amiodarone, lidocaine, and fluid boluses. Post-arrest characteristics associated with sodium bicarbonate use included higher arterial lactate and ECMO cannulation within 6 hours of CPR, and higher arterial lactate within 6-24 hours and ECMO cannulation within 24 hours.

Hemodynamic data by age and sodium bicarbonate use are shown in Supplemental Digital Content 3. Children 1 month to <1 year of age who received sodium bicarbonate were less likely to achieve average systolic blood pressure  $\geq 60$  mmHg during the first 10 minutes of CPR. Children 1 year to <8 years had lower systolic pressure 2-6 hours prior to CPR and lower average diastolic pressure during the first 10 minutes of CPR. Children 8 years to <19 years had lower average systolic pressure during the first minute of CPR.

Outcome data are reported in Table 2. Survival to hospital discharge occurred in 223 (42.2%) children who received sodium bicarbonate versus 419 (73.3%) who did not. Survival to hospital discharge with favorable neurologic outcome occurred in 202 (38.3%) who received sodium bicarbonate versus 394 (68.9%) who did not.

Sodium bicarbonate use varied by study site, and was more likely with pre-arrest acidosis ( $\text{pH} < 7.0$  or total  $\text{CO}_2 < 5$ , 2-6 hours prior to CPR), hypotension as the immediate cause of arrest and longer duration of CPR (Supplemental Digital Content 4). Except for site D and J, these variables were balanced in the propensity scoring (Supplemental Digital Content 6). Serum creatinine was also not balanced in propensity scoring. Therefore Site D, J and serum creatinine were controlled for in models estimating the effect of sodium bicarbonate on outcomes. In addition, a priori selected variables including first documented rhythm, age, illness category, and duration of CPR were controlled for in these models. Estimates of the effect of sodium bicarbonate on outcomes among the weighted cohort are shown in Table 3. Sodium bicarbonate use was not associated with ROSC. Sodium bicarbonate use was associated with decreased survival to hospital discharge and decreased survival to hospital discharge with favorable neurologic outcome. Sodium bicarbonate use was also associated with less new morbidity among survivors.

## DISCUSSION

In this contemporary multicenter analysis, we found that sodium bicarbonate is used frequently during p-IHCA and that its use is associated with worse outcomes including decreased survival to hospital discharge and decreased survival with favorable neurologic outcome. Sodium bicarbonate use was associated with child and event characteristics including cardiac diagnoses, greater illness severity and longer CPR duration. Sodium bicarbonate use was not associated with improved hemodynamics during CPR or greater likelihood of ROSC.

Despite limited AHA indications for sodium bicarbonate during p-IHCA, it was administered in almost half of CPR events in our study. Two previous registry studies reported similar findings. Raymond et al. analyzed 3719 pediatric index CPR events from 2000-2010 using data from the AHA's Get with the Guidelines Registry and found sodium bicarbonate was used in 68% of events and associated with decreased ROSC, decreased survival to discharge, and decreased survival with favorable neurologic outcome (10). Loomba et al. focused primarily on pediatric cardiac patients using data from the Pediatric Health Information System to determine patient characteristics, outcomes and billing charges associated with sodium bicarbonate use during CPR from 2004-2015 (11). In this study, 3987 (50.3%) used sodium bicarbonate however use decreased from 62.1% to 43.7% over the period of study. Sodium bicarbonate use was associated with increased mortality consistent with our findings. Our results support a declining use of sodium bicarbonate when compared to earlier reports; however, sodium bicarbonate is still used frequently and likely outside of AHA recommendations.

Similar to previous work, we found sodium bicarbonate use was associated with decreased survival to hospital discharge, decreased survival with favorable neurologic outcome and no difference in ROSC (8-10, 24-29). We also unexpectedly observed sodium bicarbonate use was associated with less new morbidity in survivors. Outcomes of p-IHCA range from mortality at one extreme, to survival with new morbidity in the middle, to intact survival at the other extreme. If sodium bicarbonate disproportionately shifts outcome among children who might otherwise have survived with new morbidity toward higher mortality, then this middle group may be smaller as a result.

We used propensity weighted analysis to account for many variables that could confound the relationship between sodium bicarbonate use and outcome. For example, prior studies by Raymond et al. and Meert et al., showed that sodium bicarbonate administration was associated with longer CPR duration even when excluding extremes (CPR events <5 min or >120 min) and longer CPR duration was associated with mortality (9,10). These authors suggest that sodium bicarbonate is often used as a "last-ditch" effort for patients who are unlikely to survive (9). In our study, to reduce the confounding effect of CPR duration, we included CPR duration in the propensity model and as a covariate in the final multivariable models. Using this doubly robust approach (22,23), we found that sodium bicarbonate use was associated with worse outcomes. However, we were not able to perform time-dependent propensity matching because the time of sodium bicarbonate administration was not available in the ICU-RESUS dataset. We also included illness category (medical cardiac, surgical cardiac and non-cardiac) in the propensity model and as a covariate to reduce confounding by cardiac diagnoses.

Mechanisms underlying increased mortality with sodium bicarbonate use are not entirely clear but include hyperosmolarity, hypokalemia, hypocalcemia, hypernatremia, intracellular acidosis, and impaired tissue oxygen delivery if administered excessively (30-33). Our findings suggest that sodium bicarbonate should be used with caution during CPR if at all.

Sodium bicarbonate use varied by clinical site, illness category and location of care (PCICU versus PICU). This likely reflects important center and provider variation and attitudes about



administration of sodium bicarbonate despite limited data to support its use (24). Children who received sodium bicarbonate had higher PRISM and VIS scores, longer CPR duration, and greater likelihood of additional resuscitation medications, PEA/asystole, ventricular tachycardia or fibrillation, and hypotension as the immediate cause of arrest than those not receiving sodium bicarbonate similar to previous reports (9,10).

Unlike previous reports, we were able to assess hemodynamics in the period immediately preceding and during CPR. In children >1 month of age, there were some differences in hemodynamic variables during CPR between treatment groups, with lower systolic and/or diastolic blood pressures in those that received sodium bicarbonate. However, since the timing of sodium bicarbonate administration was not recorded and all intra-arrest hemodynamics were within the first 10 minutes of CPR, it is possible that sodium bicarbonate was administered after these intra-arrest hemodynamic measurements. Only children 1 year of age to <8 years treated with sodium bicarbonate had lower systolic blood pressures 2-6 hours prior to CPR. Although statistically significant, these minor differences in hemodynamics between treatment groups are of unclear clinical significance. Because of the lack of data on timing of sodium bicarbonate, the extent to which sodium bicarbonate use during CPR was driven by hemodynamic responsiveness cannot be determined.

Strengths of this study include the multicenter design, prospective data collection, and robust statistical approach for reducing confounders. Although many important confounders were controlled for in our analyses, others may exist that were not collected. A major limitation is that the time of sodium bicarbonate administration was not collected. Thus, we were unable to perform time-dependent propensity matching, an approach to delineate effects of time-sensitive CPR interventions (34,35). Other limitations include the lack of intra-arrest laboratory values (e.g., potassium, pH); values collected 2-6 hours prior to CPR may not reflect those during CPR. Thus, we were not able to assess whether bicarbonate use for severe intra-arrest metabolic acidosis (e.g., pH < 7.0 or <7.1) was associated with better or worse outcomes. Hemodynamic waveforms could only be collected from children with invasive arterial catheters. Indications for sodium bicarbonate and total dose were not recorded. The majority of children included in our study were infants (<1 year) potentially limiting the ability to generalize findings to older age groups. All ICUs participating in our study were academic centers potentially limiting the ability to generalize to non-academic sites. Importantly, this is an observational study and the associations observed do not infer causation. Future directions include investigating the timing of sodium bicarbonate administration in relation to intra-arrest hemodynamics, and the use of sodium bicarbonate in specific subgroups that may have high potential to benefit such as severe intra-arrest acidosis and hyperkalemia.

## CONCLUSIONS

In this propensity weighted multicenter cohort study of p-IHCA, sodium bicarbonate was used in 48% of CPR events and was associated with lower rates of survival to hospital discharge.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Source of Funding:

This study was funded by the following grants from the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute and the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development: R01HL131544, U01HD049934, UG1HD049981, UG1HD049983, UG1HD050096, UG1HD063108, UG1HD083166, UG1HD083170, UG1HD083171, and K23HL148541.

## Copyright Form Disclosure:

Drs. Reeder, Carcillo, Carpenter, Dean, Fink, Frazier, Friess, Hall, Manga, Morgan, Mourani, Nadkarni, Naim, Palmer, Pollack, Wessel, Wolfe, Yates, Zuppa, Sutton, and Meert's institutions received funding from the National Institutes of Health (NIH). Drs. Reeder, Berg, Carcillo, Carpenter, Dean, Fink, Frazier, Friess, Hall, Horvat, Maa, McQuillen, Morgan, Mourani, Nadkarni, Naim, Palmer, Pollack, Wessel, Wolfe, Yates, Zuppa, and Meert received support for article research from the NIH. Dr. Berg's institution received funding from the National Institute of Child Health and Human Development (NICHD) CPCCRN grant and the National Heart, Lung, and Blood Institute (NHLBI) ICU-RESUS trial grant. Dr. Fink's institution received funding from the Neurocritical Care Society; she received funding from the American Board of Pediatrics and the Child Neurology Society. Dr. Friess received funding from an expert witness testimony. Dr. Hall received funding from Abbvie, La Jolla Pharmaceuticals, and Kiadis. Drs. Horvat, Maa, and McQuillen's institutions received funding from the NICHD. Dr. Horvat's institution received funding from the National Institute of Neurological Disorders and Stroke. Dr. Maa's institution received funding from the NHLBI. Dr. Mourani disclosed the off-label product use of sodium bicarbonate. Dr. Pollack disclosed work for hire. Dr. Wolfe received funding from The Debriefing Academy and Zoll. The remaining authors have disclosed that they do not have any potential conflicts of interest.

## REFERENCES

1. Morgan RW, Kirschen MP, Kilbaugh TJ, et al. : Pediatric in-hospital cardiac arrest and cardiopulmonary resuscitation in the United States. *JAMA Pediatr* 2021; 175:293–302 [PubMed: 33226408]
2. Holmberg MJ, Ross CE, Fitzmaurice GM, et al. : Annual incidence of adult and pediatric in-hospital cardiac arrest in the United States. *Circ Cardiovasc Qual Outcomes* 2019; 12:e005580 [PubMed: 31545574]
3. Ushay HM, Notterman DA: Pharmacology of pediatric resuscitation. *Pediatr Clin North Am* 1997; 44:207–233 [PubMed: 9057791]
4. Committee ECC. Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation* 2005; 13:IV1–203
5. Kleinman ME, Chameides L, Schexnayder SM, et al. : Guidelines 2005 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 14: Pediatric advanced life support. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. *Circulation* 2005; 112:167–187
6. Vanden Hoek TL, Morrison LJ, Shuster M, et al. : Guidelines 2010 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 12: Cardiac arrest in special situations. *Circulation* 2010; 122 (18\_suppl\_3):S829–861 [PubMed: 20956228]
7. Topijian AA, Raymond TT, Atkins D, et al. : Guidelines 2020 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 4: Pediatric basic and advanced life support. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. *Circulation* 2020; 142(16\_suppl\_2):S469–S523 [PubMed: 33081526]
8. Lokesh L, Kumar P, Murki S, et al. : A randomized controlled trial of sodium bicarbonate in neonatal resuscitation-effect on immediate outcome. *Resuscitation* 2004; 60:219–223 [PubMed: 15036741]
9. Meert K, Donaldson A, Nadkarni V, et al. : Multicenter cohort study of in-hospital pediatric cardiac arrest. *Pediatr Crit Care Med* 2009; 10:544–553 [PubMed: 19451846]

10. Raymond TT, Stromberg D, Stigall W, et al. : Sodium bicarbonate use during in-hospital pediatric pulseless cardiac arrest - A report from the American Heart Association Get with the Guidelines Resuscitation Investigators. *Resuscitation* 2015; 89:106–113 [PubMed: 25613362]
11. Loomba RS, Ahmed M, Abdulkarim M, et al. : Use of sodium bicarbonate during pediatric cardiac admissions with cardiac arrest: Who gets it and what does it do? *Children* 2019; 6:136
12. Reeder RW, Girling A, Wolfe H, et al. : Improving outcomes after pediatric cardiac arrest-the ICU-Resuscitation Project: Study protocol for a randomized controlled trial. *Trials* 2018; 19: 213 [PubMed: 29615134]
13. Jacobs I, Nadkarni V, Bahr J, et al. : Cardiac arrest and cardiopulmonary resuscitation outcome reports: Update and simplification of the Utstein templates for resuscitation registries. A statement for healthcare professionals from a task force of the International Liaison Committee on Resuscitation (American Heart Association, European Resuscitation Council, Australian Resuscitation Council, New Zealand Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Southern Africa). *Resuscitation* 2004; 63:233–249 [PubMed: 15582757]
14. Nolan JP, Berg RA, Andersen LW, et al. : Cardiac arrest and cardiopulmonary resuscitation outcome reports: Update of the Utstein Resuscitation Registry Template for In-Hospital Cardiac Arrest: A consensus report from a task force of the International Liaison Committee on Resuscitation (American Heart Association, European Resuscitation Council, Australian and New Zealand Council on Resuscitation, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Southern Africa, Resuscitation Council of Asia). *Circulation* 2019; 140:e746–e757 [PubMed: 31522544]
15. Berg RA, Sutton RM, Reeder RW, et al. : Association between diastolic blood pressure during pediatric in-hospital cardiopulmonary resuscitation and survival. *Circulation* 2018; 137:1784–1795 [PubMed: 29279413]
16. Morgan RW, Landis WP, Marquez A, et al. : Hemodynamic effects of chest compression interruptions during pediatric in-hospital cardiopulmonary resuscitation. *Resuscitation* 2019; 139:1–8 [PubMed: 30946924]
17. Pollack MM, Holubkov R, Funai T, et al. : The Pediatric Risk of Mortality Score: Update 2015. *Pediatr Crit Care Med* 2016; 17:2–9
18. Gaies MG, Jeffries HE, Niebler RA, et al. : Vasoactive-inotropic score is associated with outcome after infant cardiac surgery: an analysis from the Pediatric Cardiac Critical Care Consortium and Virtual PICU System Registries. *Pediatr Crit Care Med* 2014; 15:529–537 [PubMed: 24777300]
19. Fiser DH, Long N, Roberson PK, et al. : Relationship of pediatric overall performance category and pediatric cerebral performance category scores at pediatric intensive care unit discharge with outcome measures collected at hospital discharge and 1- and 6-month follow-up assessments. *Crit Care Med* 2000; 28: 2616–2610 [PubMed: 10921604]
20. Pollack MM, Holubkov R, Funai T, et al. : Relationship between the functional status scale and the pediatric overall performance category and pediatric cerebral performance category scales. *JAMA Pediatr* 2014; 168:671–676 [PubMed: 24862461]
21. Haukoos JS, Lewis RJ: The propensity score. *JAMA* 2015; 314(15):1637–1638 [PubMed: 26501539]
22. Funk MJ, Westreich D, Wiesen C, et al. : Doubly robust estimation of causal effects. *Am J Epidemiol* 2011; 173(7):761–767 [PubMed: 21385832]
23. Bang H, Robins JM: Doubly robust estimation in missing data and causal inference models. *Biometrics* 2005; 61(4):962–973 [PubMed: 16401269]
24. Parker MJ, Parshuram CS: Sodium bicarbonate use in shock and cardiac arrest: Attitudes of pediatric acute care physicians. *Crit Care Med* 2013; 41:2188–2195 [PubMed: 23760153]
25. Mok YH, Loke AP, Loh TF, et al. : Characteristics and risk factors for mortality in paediatric in-hospital cardiac events in Singapore: Retrospective single centre experience. *Ann Acad Med Singapore* 2016; 45:534–541 [PubMed: 28062881]
26. Chang CY, Wu PH, Hsaio CT, et al. : Sodium bicarbonate administration during in-hospital pediatric cardiac arrest: A systematic review and meta-analysis. *Resuscitation* 2021; 161:188–197

27. Aschner JL, Poland RL: Sodium bicarbonate: Basically useless therapy. *Pediatrics* 2008; 122:831–835 [PubMed: 18829808]
28. Sutton RM, Reeder RW, Landis W, et al. : Chest compression rates and pediatric in-hospital cardiac arrest survival outcomes. *Resuscitation* 2018; 130:159–166 [PubMed: 30031055]
29. Lopez-Herce J, Del Castillo J, Matamoros M, et al. : Factors associated with mortality in pediatric in-hospital cardiac arrest: A prospective multicenter multinational observational study. *Intensive Care Med* 2013; 39:309–318 [PubMed: 23184036]
30. Wayne MA, Delbridge TR, Ornato JP, et al. : Concepts and application of prehospital ventilation. *Prehosp Emerg Care* 2001; 5:73–78 [PubMed: 11194074]
31. Adeva-Andany MM, Fernandez-Fernandez C, Mourino-Bayolo D, et al. : Sodium bicarbonate therapy in patients with metabolic acidosis. *Sci World J* 2014; 2014:627673
32. Mattar JA, Weil MH, Shubin H, et al. : Cardiac arrest in the critically ill. II. Hyperosmolar states following cardiac arrest. *Am J Med* 1974; 56:162–168 [PubMed: 4812073]
33. Bishop RL, Weisfeldt ML: Sodium bicarbonate administration during cardiac arrest. Effect on arterial pH, PCO<sub>2</sub>, and osmolality. *JAMA* 1976; 235:506–509 [PubMed: 1554]
34. Anderson LW, Raymond TT, Berg RA, et al. : Association between tracheal intubation during pediatric in-hospital cardiac arrest and survival. *JAMA* 2016; 316:1786–1797 [PubMed: 27701623]
35. Anderson LW, Berg KM, Saindon BZ, et al. : Time to epinephrine and survival after pediatric in-hospital cardiac arrest. *JAMA* 2015; 314:802–810 [PubMed: 26305650]

### Report in Context

- Sodium bicarbonate use during p-IHCA has been associated with increased mortality in retrospective reports.
- Most of what is known about sodium bicarbonate in p-IHCA comes from single-center or registry studies which, though important, have notable limitations.
- This report contains multicenter prospective data focused on factors associated with sodium bicarbonate use during p-IHCA and outcomes.

**At the Bedside**

- In a multicenter prospective cohort, sodium bicarbonate was used in almost half of CPR events.
- Sodium bicarbonate use was associated with increased mortality.
- Sodium bicarbonate should be used with caution if at all during p-IHCA.

**Table 1.**

## Patient characteristics by sodium bicarbonate use

	<b>Sodium bicarbonate</b>	
	<b>Yes (N = 528)</b>	<b>No (N = 572)</b>
Demographics		
Age		
1 month	100 (18.9%)	73 (12.8%)
1 month - < 1 year	206 (39.0%)	258 (45.1%)
1 year - < 8 years	113 (21.4%)	150 (26.2%)
8 years - < 19 years	109 (20.6%)	91 (15.9%)
Male	293 (55.5%)	296 (51.7%)
Weight (kg)	7.2 [4.0,18.7]	6.8 [4.1,14.4]
Preexisting medical conditions		
Respiratory insufficiency	440 (83.3%)	505 (88.3%)
Hypotension	399 (75.6%)	294 (51.4%)
Congestive heart failure	79 (15.0%)	61 (10.7%)
Pneumonia	56 (10.6%)	78 (13.6%)
Sepsis	104 (19.7%)	74 (12.9%)
Renal insufficiency	76 (14.4%)	69 (12.1%)
Malignancy	31 (5.9%)	20 (3.5%)
Trauma	18 (3.4%)	16 (2.8%)
Pulmonary hypertension	81 (15.3%)	100 (17.5%)
Congenital heart disease	325 (61.6%)	307 (53.7%)
Single ventricle heart disease	26 (4.9%)	11 (1.9%)

**Table 2.**

Summary of outcomes by sodium bicarbonate use

	<b>Sodium bicarbonate use</b>		<b>Overall (N = 1100)</b>
	<b>Yes (N = 528)</b>	<b>No (N = 572)</b>	
Return of spontaneous circulation <sup>a</sup>	260 (49.2%)	513 (89.7%)	773 (70.3%)
Survival to hospital discharge	223 (42.2%)	419 (73.3%)	642 (58.4%)
Survival to hospital discharge with favorable neurologic outcome <sup>b,c</sup>	202 (38.3%)	394 (68.9%)	596 (54.2%)
Survival to hospital discharge with PCPC of 1, 2, or no worse than baseline	185 (35.0%)	360 (62.9%)	545 (49.5%)
Change from baseline to hospital discharge in functional status of survivors <sup>b</sup>	1.0 [0.0,3.0]	1.0 [0.0,3.0]	1.0 [0.0,3.0]
New morbidity among survivors <sup>d</sup>	73/223 (32.7%)	123/419 (29.4%)	196/642 (30.5%)

PCPC = Pediatric Cerebral Performance Category

<sup>a</sup>Return of spontaneous circulation reported is the immediate outcome of the resuscitation event.<sup>b</sup>Baseline PCPC and FSS represent child status prior to the event leading to hospitalization.<sup>c</sup>Favorable neurologic outcome is defined as no more than moderate disability or no worsening from baseline Pediatric Cerebral Performance Category (PCPC).<sup>d</sup>New morbidity among survivors is defined as a worsening from baseline functional status by 3 points or more.



**Table 3.**

Estimated effect of sodium bicarbonate use on outcomes

Outcome	Adjusted odds ratio (95% CI)	Mean difference (95% CI)	P-value
Return of spontaneous circulation <sup>a</sup>	0.91 (0.62, 1.34)		0.621
Survival to hospital discharge	0.70 (0.54, 0.92)		0.010
Survival to hospital discharge with favorable neurologic outcome <sup>b,c</sup>	0.69 (0.53, 0.91)		0.007
Survival to hospital discharge with PCPC of 1, 2, or no worse than baseline	0.80 (0.62, 1.05)		0.105
Change from baseline to hospital discharge in functional status of survivors <sup>b</sup>		-0.39 (-0.90, 0.13)	0.139
New morbidity among survivors <sup>d</sup>	0.67 (0.45, 0.98)		0.038

Models were weighted using stabilized inverse probability of treatment weights and additionally controlled for site D, site J, creatinine, first documented rhythm, age, illness category and CPR duration.

<sup>a</sup>Return of spontaneous circulation reported is the immediate outcome of the resuscitation event.

<sup>b</sup>Baseline Pediatric Cerebral Performance Category (PCPC) and Functional Status Scale (FSS) represent subject status prior to the event leading to hospitalization.

<sup>c</sup>Favorable neurologic outcome is defined as no more than moderate disability or no worsening from baseline Pediatric Cerebral Performance Category (PCPC).

<sup>d</sup>New morbidity among survivors is defined as a worsening from baseline functional status by 3 points or more.